Antisense Oligonucleotides for Selective Huntingtin Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Huntington's disease is a neurodegenerative disorder caused by a mutation in the huntingtin gene, leading to progressive motor, emotional, and cognitive symptoms, with existing treatments lacking effective mechanisms to reduce mutant huntingtin protein expression without affecting wild-type levels.
Innovation Solution
Development of antisense oligonucleotides targeting specific sequences of the huntingtin gene to modulate its expression, specifically designed for delivery to the central nervous system via intrathecal, intracerebroventricular, or intraparenchymal routes, reducing mutant huntingtin mRNA and protein levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If existing treatments are used, then general symptom management is achieved, but effective reduction of mutant huntingtin protein expression is not achieved
Solution Approach 1:
The antisense oligonucleotide is designed with a specific sequence that is complementary only to the mutant huntingtin mRNA sequence containing the expanded CAG repeats. This local specificity allows the oligonucleotide to bind selectively to mutant transcripts while leaving wild-type huntingtin mRNA unaffected, thereby reducing mutant protein expression without compromising wild-type protein levels.
Solution Approach 2:
The invention exploits the specific parameter difference in the CAG repeat length between mutant and wild-type huntingtin genes. By designing the antisense oligonucleotide to target sequences within the expanded repeat region or adjacent areas that are unique to the mutant allele, the treatment achieves selective inhibition based on this sequence parameter variation.
2Quantity of substance
If antisense oligonucleotides are designed to target huntingtin gene, then mutant huntingtin expression is reduced, but delivery to central nervous system becomes challenging
Solution Approach 1:
The patent describes intrathecal administration as an intermediary delivery method that bypasses the blood-brain barrier. By injecting the antisense oligonucleotide into the cerebrospinal fluid space, the treatment achieves direct access to the central nervous system without requiring systemic circulation, thereby improving delivery efficiency and reducing the complexity of administration.
3Reliability
If antisense oligonucleotides are administered intrathecally, then delivery to central nervous system is improved, but treatment complexity increases
Solution Approach 1:
The invention extracts the antisense oligonucleotide from complex delivery systems and administers it as a relatively simple intrathecal injection. This approach removes the need for complex targeted delivery systems, viral vectors, or invasive surgical implantation, thereby simplifying the overall treatment protocol while maintaining reliable delivery to the central nervous system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense oligonucleotides effectively inhibit huntingtin expression, slowing disease progression, delaying onset, and increasing survival time by reducing neuronal aggregates and improving clinical indicators of Huntington's disease.
Implementation Method 1
antisense oligonucleotides targeting specific sequences of the huntingtin gene to modulate its expression
Data Source
AI summary
Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.